Live
Endpoints NewsVertex drops mRNA cystic fibrosis program over 'tolerability' issuesFierceBiotechVertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issuesClinical OMICsNatural Compounds in Cranberry Juice May Enhance Antibiotic Treatment of UTIsClinical OMICsBreast Cancer Prevention Drug Endoxifen Shows Promise at Low DosesFierceBiotechPassage launches strategic review and 75% layoffs after gene therapy path blocked by FDAIlluminaFinal Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBCEndpoints NewsFDA search for new CBER head focused on small group of final candidatesFierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and ChinaBioPharma DiveCelcuity strengthens case for ASCO-spotlighted breast cancer drugEndpoints NewsSupreme Court restores mifepristone access by mailClinical OMICsBiomarker of Epigenetic Aging Could Signal DepressionBioWorldAppointments and advancements for May 4, 2026
Endpoints News Mar 20, 2026

Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesity

Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesity

Original
Body unavailable. Use the original source.